Cyclica and AUM Biosciences Collaborate to Develop Novel Cancer Therapies Under Project Nexus

 Cyclica and AUM Biosciences Collaborate to Develop Novel Cancer Therapies Under Project Nexus

Cyclica and AUM Biosciences Collaborate to Develop Novel Cancer Therapies Under Project Nexus

Shots:

  • Cyclica to receive up front, milestones upon completion of specific stages for Project Nexus. AUM to get right to develop & commercialize therapies resulting from Project Nexus
  • The collaboration leverages AUM’s drug development expertise including its biomarker-driven approach with Cyclica’s AI-augmented and structure-based platform, Ligand Design and Ligand Express
  • The companies will design molecules with greater precision and speed, minimizing unwanted off-target effects while providing an understanding of their activity via systems biology and structural pharmacogenomics, addressing the unmet medical needs of patients in Asia

Click here ­to­ read full press release/ article | Ref: Business wire | Image: AUM Bioscience

Leave a Reply

Your email address will not be published. Required fields are marked *